ZIM Labs Strengthens Market Play with CDSCO Approvals & Strategic Tie-Up

ZIM Laboratories Ltd has announced two significant developments that strengthen its growth trajectory in India’s pharmaceutical sector. The company has signed a supply agreement with an Indian pharma company, paving the way for a product launch in FY27. In parallel, ZIM has also received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for two key formulations: Naproxen (a widely used anti-inflammatory drug) and Esomeprazole (a proton pump inhibitor for acid-related disorders).

 

Key Highlights

These moves highlight ZIM Laboratories’ proactive approach to growth, combining regulatory success with strategic alliances.

 

Sources: Reuters (RTRS), Exchange Filings